Our approach to therapeutic antibodies : Our Pipeline
Kyowa Kirin has a number of high-quality foundational technologies that can be used to efficiently create therapeutic antibodies. These include antibody technologies such as our revolutionary POTELLIGENT® platform, which enhances the potency and efficacy of antibodies.
In addition, we focus on R&D investment for sustainable growth, and to ensure we are bringing more value to patients in need. One way we do this is by developing therapeutic antibody programs utilizing our proprietary bispecific technology, "REGULGENT™".
We are leveraging our expertise in protein and antibody engineering and sugar-control technologies that we have developed over years of experience. We are also actively engaged in collaborative research with research institutions to advance next-generation therapeutic antibodies, such as immunostimulatory antibodies and tissue- directed antibodies.
